BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//7.2.3.1//EN
BEGIN:VEVENT
UID:645@biocityturku.fi
DTSTART;TZID=Europe/Helsinki:20241203T140000
DTEND;TZID=Europe/Helsinki:20241203T150000
DTSTAMP:20241125T091810Z
URL:https://biocityturku.fi/events/immunology-seminar-5/
SUMMARY:Immunology Seminar: Dufva
DESCRIPTION:3rd December 14-15\nVirtual event\nIn Zoom\nFlyer\n\nDr. Olli D
 ufva\, Wellcome Sanger Insitute\, Cambridge Stem Cell Institute\, Universi
 ty of Cambridge\, UK\nSingle-cell functional genomics of natural killer ce
 ll evasion in cancer\n\nHost: Riitta Lahesmaa (rilahes@utu.fi)\n\nRegister
  for the Immunology Seminar Series email list to get calendar invitation t
 o the online seminar: https://link.webropolsurveys.com/S/D29C32AA6E8A2F7A\
 n\nImmunology seminar series is jointly organised by the Finnish Society f
 or Immunology\, InFLAMES Flagship and Turku Bioscience. For further inform
 ation contact Anne Lahdenperä  (ankahy@utu.fi) or Riitta Lahesmaa (rilah
 es@utu.fi)\, University of Turku.\n\n&nbsp\;\n\nOlli Dufva is a physician-
 scientist and a postdoctoral fellow at the Wellcome Sanger Institute and U
 niversity of Cambridge in the laboratories of Prof Sarah Teichmann and Dr 
 Mathew Garnett. His research focuses on deciphering genomic determinants o
 f anti-cancer immunity and developing improved cellular immunotherapies us
 ing single-cell genomics\, organoid models and genetic engineering. Olli c
 ompleted his medical degree and his PhD at the University of Helsinki\, wh
 ere he studied immune interactions and precision medicine in blood cancers
  with Prof Satu Mustjoki. This year Olli Dufva was awarded the ACTERIA Doc
 toral Thesis Prize in Immunology for his work on “Functional Immunogenom
 ics in Hematological Malignancies”.\n\nOlli’s work at the intersection
  of immunology and cancer has included mapping the immunogenomic landscape
  of blood cancers by integrating transcriptomic and multi-omic data across
  thousands of patient samples and applying high-throughput drug screens\, 
 CRISPR screens\, and single-cell analysis to lymphocyte – cancer cell co
 -cultures to find immunotherapy-enhancing drugs and genetic resistance mec
 hanisms.\n\n&nbsp\;\n\nSelected publications\n\nDufva O\, Gandolfi S\, …
 \, Mitsiades CS\, Mustjoki S. Single-cell functional genomics reveals dete
 rminants of sensitivity and resistance to natural killer cells in blood ca
 ncers. Immunity. 2023 doi: 10.1016/j.immuni.2023.11.008\n\nDufva O\, Pöl
 önen P\, …\, Heinäniemi M\, Mustjoki S. Immunogenomic Landscape of Hem
 atological Malignancies. Cancer Cell. 2020 doi: 10.1016/j.ccell.2020.06.00
 2\n\nDufva O\, Koski J\, Maliniemi P\,  …\, Keränen MAI\, Korhonen M\
 , Mustjoki S. Integrated drug profiling and CRISPR screening identify esse
 ntial pathways for CAR T-cell cytotoxicity. Blood. 2020 doi: 10.1182/blood
 .2019002121
ATTACH;FMTTYPE=image/jpeg:https://biocityturku.fi/wp-content/uploads/2023/
 11/general-molecules-thumbnail.jpg
CATEGORIES:Other events
END:VEVENT
BEGIN:VTIMEZONE
TZID:Europe/Helsinki
X-LIC-LOCATION:Europe/Helsinki
BEGIN:STANDARD
DTSTART:20241027T030000
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
END:STANDARD
END:VTIMEZONE
END:VCALENDAR